Efficacy and safety of switching to bimatoprost or dorzoramide/timolol fixed-combination therapy from latanoprost monotherapy

Efficacy and safety of switching to bimatoprost or dorzoramide/timolol fixed-combination therapy from latanoprost monotherapy - Change to bimatoprost or dorzoramide/timolol from latanoprost

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010081

Enrollment

Registered

2013-02-20

Start date

2013-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open angle glaucoma or ocular hypertension

Interventions

One eye randomly changed to bimatoprost ophthalmic sollutions from latanoprost ophthalmic solution. Latanoprost ophthalmic solution was resumed 12 weeks later. The other eye changed to dorzoramide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with primary open angle glaucoma or ocular hypertension

Exclusion criteria

Exclusion criteria: Other severe ocular diseases Contra-indication for experiment ophthalmic solutions Problems for intra-ocular pressure measurement

Design outcomes

Primary

Measure	Time frame
Intra-ocular pressure	—

Secondary

Measure	Time frame
Ocular adverse effects	—

Countries

Japan

Contacts

Public ContactKenji Kashiwagi

University of Yamanashi Department of Ophthalmology

055-273-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026